Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Metals lead the losses
Thu, 29 Sep 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in South Korea (up 1.1%), Taiwan (up 0.3%) and Indonesia (up 0.2%) are trading firm, while markets in China (down 0.8%), Japan (down 0.4%) and Singapore (down 0.3%) are facing selling pressure. The Indian stock markets have opened the day on a weak note. Metal, capital goods and consumer durable stocks are leading the losses.

The BSE-Sensex is trading lower by around 97 points (0.6%), the NSE-Nifty is down by around 28 points (0.6%). The midcap and smallcap stocks are in the negative as well with both the BSE Mid Cap and BSE Small Cap indices down by 0.5% and 0.3% respectively. The rupee is trading at 48.93 to the US dollar.

Pharma Stocks have opened the day in the red with Sun Pharma, Glenmark Pharma, Cipla, Cadila Healthcare and Divi's Lab facing selling pressure. According to a company spokesperson, Indian drug manufacturer Glenmark Pharmaceuticals has launched malaria treatment drug atovaquone and proguanil hydrochloride in the US. Atovaquone and proguanil hydrochloride tablets are generic equivalent of GlaxoSmithKline's brand Malarone. Glenmark had settled a patent litigation with GlaxoSmithKline in April 2010. Post settlement, Glenmark has been permitted to launch the generic tablets in the US on royalty-bearing licence in the third quarter of calendar year 2011 (3QCY11). Malarone had reported revenues of US$ 56 m in 2009 in the US.

Oil & Gas stocks have opened the day on a weak note with Cairn India, Reliance Industries, Essar Oil and Petronet LNG leading the losses. British Petroleum (BP) group chief visited India for the first time after BP-Reliance Industries alliance got the Government nod. The chief said that the two entities have set up a joint team which will study the possibility of increasing D6 gas fields output. The team is evaluating the potential to add production from other blocks such as NEC 25, and developing other exploration options. The BP Chief is confident that they will be able to increase output by their efforts within time. Both the BP chief and Mr Mukesh Ambani have met senior ministers of India during former's visit. The consumers and government are concerned due to the decline in D6 output. The output which was once at the peak of 60 mmscmd (million metric standard cubic meter per day) in 2009 has been consistently dipping since then. Currently, RIL is producing around 42 mmscmd from the fields and further decline is expected over a period of time.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Metals lead the losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.